ASPEN PHARMACARE HOLDINGS LIMITED - South African13 Jun 2017
APN 201706130039A
South African Competition Commission Announcement

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (˘Aspen Holdings÷)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively ˘Aspen÷ or ˘the Aspen Group÷)




South African Competition Commission Announcement

Aspen has noted the announcement by the South African Competition Commission that it will be
investigating Aspen for suspected abuse of dominance in respect of the provision of cancer medication
in South Africa.

Aspen is committed to full and constructive engagement with the Competition Commission in this
investigation.

It is reiterated that pharmaceutical prices in South Africa are approved by the Department of Health in
terms of the Single Exit Price regulatory framework which establishes a universal fixed price for each
pharmaceutical product. Aspen has not increased pricing of its products outside of this regulatory
framework and has clearly demonstrated its commitment to providing quality medicines affordably over
many years. The supply of the oncology products in question is no exception.



Durban

13 June 2017



Sponsor:

Investec Bank Limited

Date: 13/06/2017 03:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.